Retina

Ophthalmology Times® talked with Edmund Arthur, OD, PhD, FAAO, about his research on the early detection of diabetic retinopathy in underserved communities at this year's ARVO meeting.

Ophthalmology Times® talked with Jay Barth, MD, about the work at Ascidian Therapeutics and their research into developing a new way to administer gene therapy at this year's ARVO meeting.

Hydrogen water intake improved retinal blood flow (RBF) dysregulation in response to flicker stimulation and systemic hyperoxia in type 2 diabetic mice.

Thomas V. Johnson, MD, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at this year's ARVO meeting on retinal engineering and RGC replacement.

Japanese investigators have found an ocular biomarker of cardiovascular diseases.

AVA-Net is a deep-learning network developed by scientists from the University of Illinois at Chicago.

Reducing treatment burden, finding something other than a shot a month is key.

During a presentation at the Vit-Buckle Society meeting in Las Vegas, Sally S. Ong, MD, highlighted a new study of patients who underwent primary repair of uncomplicated RRDs at the Wilmer Eye Institute to examine the baseline, surgical and postoperative characteristics that affect best-corrected VA outcomes.

As technology advances, innovations increase physician capabilities.

A large cohort study found that there is no association between the first mRNA COVID-19 vaccinations and acute RVO.

Jennifer Lim, MD, FARVO sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss her presentation at this year's Vit-Buckle Society meeting on keratoprosthesis combined with vitrectomy surgery.

Daraius Shroff, MD, developed the Triple S toolkit for hAM grafting for use during vitreoretinal surgery, which he described at the 2023 Vit-Buckle Annual Society meeting.

J. Peter Campbell, MD, MPH, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss pediatric retina surgery and 3 key pearls to consider while performing the surgery.

Patients and employees, past and present, have had personal and protected health information acquired without authorization.

According to National Eye Institute researchers, the variants generate malformed proteins that alter the stability of the membrane attack complex, which may drive a chronic inflammatory response in the retina.

By crossing into the retina, investigators have uncovered a new DHA supplement achieves what previous ones could not.

Retinal redetachment can occur frequently in eyes that underwent repair of rhegmatogenous retinal detachments (RRDs) after infectious endophthalmitis.

According to National Eye Institute researchers, the strategy may speed the delivery of therapeutic options relative to time it would take to develop gene therapies.

According to the company, clinically meaningful visual acuity gains were observed in several MCO-010 treated patients. The trial also demonstrated a favorable safety profile for MCO-010 with no serious or severe adverse events.

Researchers at Buck Institute, working with Google Health and Zuckerberg San Francisco General Hospital, are studying the eye as a window into human aging.

According to researchers at UCLA, “dormant” cone photoreceptors might continue to drive retinal activity for vision.

Nitish Mehta, MD discusses the latest trends in Artificial Intelligence and Machine Learning technology in retinal imaging and its uses for ophthalmologists.

Learning more about the early AD stages, when brain damage is limited, should allow early and more efficacious treatment, and improvements in imaging may be able to pick up changes earlier.

According to researchers, diabetes mellitus is caused by higher levels of blood glucose due to the lack of production of insulin by the body, resistance to insulin, or both.

This subtype of artificial intelligence technology may have long-range implications for clinical trials.

According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.

Researchers conducted a retrospective analysis of longitudinal, clinical data from patients with high myopic MNV treated with intravitreal bevacizumab.

According to researchers, patients with chronic CSC treated with 1 fovea-involving, half-dose PTD application had a significant improvement in structure and function at the final follow-up and foveal atrophy did not develop in any patients.

Primary vitreoretinal lymphoma is a rare, aggressive, and potentially fatal retinal cancer that is diagnosed in approximately 300 to 600 patients in the United States per year.

Despite its promise, RGC replacement represents a more formidable challenge.